The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment

被引：38
|
作者：
Qin, Hanjiao [1 ]
Liu, Linlin [1 ]
Sun, Shu [2 ]
Zhang, Dan [3 ]
Sheng, Jiyao [3 ]
Li, Bingjin [4 ]
Yang, Wei [4 ]
机构：
[1] Jilin Univ, Hosp 2, Dept Radiotherapy, Changchun, Jilin, Peoples R China
[2] Changchun Univ Tradit Chinese Med, Affiliated Hosp, Changchun, Jilin, Peoples R China
[3] Jilin Univ, Hosp 2, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
[4] Jilin Univ, Hosp 2, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China
来源：
PEERJ | 2018年 / 6卷
关键词：
Breast cancer; PI3K; Pathway inhibitors; Tumor microenvironment; Combination therapy; REGULATORY T-CELLS; PATHOLOGICAL COMPLETE RESPONSE; ESTROGEN-RECEPTOR-ALPHA; PIK3CA MUTATIONS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL; 3-KINASE; PHOSPHOINOSITIDE; PHASE IB; ANTIESTROGEN RESISTANCE; P110-ALPHA ISOFORM;
D O I：
10.7717/peerj.5092
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway shows frequent aberrant alterations and pathological activation in breast cancer cells. While PI3K inhibitors have not achieved expectant therapeutic efficacy in clinical trials, and several studies provide promising combination strategies to substantially maximize therapeutic outcomes. Besides its direct impact on regulating cancer cells survival, PI3K inhibitors are also demonstrated to have an immunomodulatory impact based on the tumor microenvironment. Inhibition of the leukocyte-enriched PI3K isoforms may break immune tolerance and restore cytotoxic T cell activity by reprogramming the tumor microenvironment. In addition, PI3K inhibitors have pleiotropic effects on tumor angiogenesis and even induce tumor vascular normalization. In this review, we discuss the mechanism of PI3K inhibitor suppression of breast cancer cells and modulation of the tumor microenvironment in order to provide further thoughts for breast cancer treatment.
引用
收藏
页数：27
相关论文
共 50 条
  • [1] The Impact of PI3K Inhibitors for the Treatment of Patients with Breast Cancer
    Traina, Tiffany A.
    [J]. ONCOLOGY-NEW YORK, 2020, 34 (01): : 28 - 31
  • [2] PI3K Inhibitors in Breast Cancer Therapy
    Haley Ellis
    Cynthia X. Ma
    [J]. Current Oncology Reports, 2019, 21
  • [3] PI3K Inhibitors in Breast Cancer Therapy
    Ellis, Haley
    Ma, Cynthia X.
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (12)
  • [4] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    [J]. Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [5] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    [J]. CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [6] Development of PI3K inhibitors in breast cancer.
    Ma, Cynthia X.
    [J]. MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 22 - 23
  • [7] Efficacy of PI3K inhibitors in advanced breast cancer
    Verret, B.
    Cortes, J.
    Bachelot, T.
    Andre, F.
    Arnedos, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 12 - 20
  • [8] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    [J]. Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [9] PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment
    Liu, Xiaoyan
    Xu, Yan
    Zhou, Qing
    Chen, Minjiang
    Zhang, Yu
    Liang, Hongge
    Zhao, Jing
    Zhong, Wei
    Wang, Mengzhao
    [J]. FUTURE ONCOLOGY, 2018, 14 (07) : 665 - 674
  • [10] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    [J]. Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
12345